Revenue (Tables)

3 Months Ended

Mar. 31, 2022

Revenue from Contract with Customer [Abstract]

The following table summarizes our revenue recognized in our consolidated condensed statements of operations:


	Three Months Ended March 31,
	2022		2021
Net product revenue	$	7,132.9	$	6,320.0
Collaboration and other revenue(1)	677.1		485.6
Revenue	$	7,810.0	$	6,805.6

(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $53.2 million and $43.0 million during the three months ended March 31, 2022 and 2021, respectively.

The following table summarizes revenue by product for the three months ended March 31, 2022 and 2021:


	Three Months Ended March 31,
	2022						2021
	U.S.		Outside U.S.		Total		U.S.		Outside U.S.		Total
Revenue—to unaffiliated customers:
Diabetes:
Trulicity®	$	1,313.9	$	427.4	$	1,741.3	$	1,116.8	$	335.7	$	1,452.4
Humalog® (1)	368.9		249.3		618.2		332.7		284.4		617.0
Jardiance(2)	229.8		189.7		419.4		151.2		160.8		312.0
Humulin®	190.4		82.8		273.2		219.0		102.7		321.7
Basaglar®	119.3		72.2		191.5		175.2		71.4		246.6
Other diabetes	54.3		90.2		144.6		66.3		94.9		161.4
Total diabetes	2,276.6		1,111.6		3,388.2		2,061.2		1,049.9		3,111.1

Oncology:
Verzenio®	301.5		167.9		469.4		172.8		96.2		269.0
Alimta®	254.3		89.7		343.9		261.1		297.8		559.0
Cyramza®	79.2		151.1		230.3		80.2		160.3		240.5
Erbitux®	109.7		13.0		122.7		107.9		14.4		122.4
Tyvyt®	—		85.5		85.5		—		109.7		109.7
Other oncology	39.0		62.0		101.2		20.5		51.3		71.6
Total oncology	783.7		569.2		1,353.0		642.5		729.7		1,372.2

Immunology:
Taltz®	307.2		180.8		488.1		249.6		153.6		403.2
Olumiant® (3)	71.3		184.3		255.6		24.7		169.1		193.8
Other immunology	—		4.5		4.5		10.5		6.4		16.9
Total immunology	378.5		369.6		748.1		284.8		329.1		613.9

Neuroscience:
Emgality®	108.3		41.0		149.3		101.5		18.0		119.5
Zyprexa®	9.6		83.5		93.1		6.9		88.9		95.8
Cymbalta®	9.1		71.9		81.1		11.0		165.7		176.6

Other neuroscience	26.4		48.0		74.2		22.3		51.1		73.5
Total neuroscience	153.4		244.4		397.7		141.7		323.7		465.4


Other:
COVID-19 antibodies(4)	1,455.2		14.7		1,469.8		650.6		159.5		810.1
Cialis®	6.9		210.8		217.7		8.6		118.1		126.8
Forteo®	70.2		67.3		137.4		97.7		100.8		198.5
Other	50.1		47.8		98.1		54.2		53.4		107.5
Total other	1,582.4		340.6		1,923.0		811.1		431.8		1,242.9
Revenue	$	5,174.6	$	2,635.4	$	7,810.0	$	3,941.3	$	2,864.3	$	6,805.6

Numbers may not add due to rounding.

(1) Humalog revenue includes insulin lispro.

(2) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.

(3) Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.

(4) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.

The following table summarizes revenue by geographical area:


	Three Months Ended March 31,
	2022		2021
Revenue—to unaffiliated customers(1):
U.S.	$	5,174.6	$	3,941.3
Europe	1,067.3		1,321.2
Japan	410.2		571.8
China	406.5		362.2
Other foreign countries	751.5		609.1
Revenue	$	7,810.0	$	6,805.6

Numbers may not add due to rounding.

(1) Revenue is attributed to the countries based on the location of the customer.

Schedule of amounts recorded for contract liabilities

The following table summarizes contract liability balances:


	March 31, 2022		December 31, 2021
Contract liabilities	$	251.6	$	262.6